These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 32460460)

  • 1. Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response.
    Woo HY; Park JY; Bae SH; Kim CW; Jang JY; Tak WY; Kim DJ; Kim IH; Heo J; Ahn SH
    Clin Mol Hepatol; 2020 Jul; 26(3):352-363. PubMed ID: 32460460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.
    Park JG; Park SY
    Clin Mol Hepatol; 2015 Sep; 21(3):242-8. PubMed ID: 26523269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir.
    Park H; Park JY; Kim SU; Kim DY; Han KH; Chon CY; Ahn SH
    World J Gastroenterol; 2013; 19(43):7671-9. PubMed ID: 24431895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
    Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
    World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir.
    Lim YS; Lee JY; Lee D; Shim JH; Lee HC; Lee YS; Suh DJ
    Antimicrob Agents Chemother; 2012 Jun; 56(6):2941-7. PubMed ID: 22430972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of lamivudine plus adefovir therapy versus entecavir with or without adefovir therapy for adefovir-resistant chronic hepatitis B.
    Kang SH; Yim HJ; Kim HR; Kang K; Suh SJ; Lee HJ; Yoon EL; Kim JH; Seo YS; Yeon JE; Byun KS
    J Clin Gastroenterol; 2014; 48(10):889-95. PubMed ID: 24440937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir.
    Ze E; Baek EK; Lee JJ; Chung HW; Ahn DG; Cho HJ; Kwon JC; Kim HJ; Lee H
    Clin Mol Hepatol; 2014 Sep; 20(3):267-73. PubMed ID: 25320730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Compare the effect of combined therapy between telbivudine plus adefovir dipivoxil and lamivudine plus adefovir dipivoxil corresponding to renal function in patients with hepatitis B virus infection].
    Xu J; Bao L; Wang Y; Yang L; Li WT; Zhao ZH; Li Y
    Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):288-293. PubMed ID: 29996341
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
    Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
    Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains.
    Lee YB; Lee JH; Lee DH; Cho H; Ahn H; Choi WM; Cho YY; Lee M; Yoo JJ; Cho Y; Cho EJ; Yu SJ; Kim YJ; Yoon JH; Kim CY; Lee HS
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6710-6. PubMed ID: 25155601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies.
    Kim HS; Yim HJ; Jang MK; Park JW; Suh SJ; Seo YS; Kim JH; Kim BH; Park SJ; Lee SH; Kim SG; Kim YS; Lee JI; Lee JW; Kim IH; Kim TY; Kim JW; Jeong SH; Jung YK; Park H; Hwang SG;
    World J Gastroenterol; 2015 Oct; 21(38):10874-82. PubMed ID: 26478678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.
    Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC
    J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B.
    Park MS; Kim BK; Kim KS; Kim JK; Kim SU; Park JY; Kim DY; Baartarkhuu O; Han KH; Chon CY; Ahn SH
    Clin Mol Hepatol; 2013 Mar; 19(1):29-35. PubMed ID: 23593607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
    Lu JJ; Liu K; Ma YJ; Wang J; Chen EQ; Tang H
    J Viral Hepat; 2013 Apr; 20 Suppl 1():40-5. PubMed ID: 23458523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil].
    Xing J; Han T; Liu L; Li Y; Li J; Li Y; Xiao SX
    Zhonghua Gan Zang Bing Za Zhi; 2011 Nov; 19(11):828-32. PubMed ID: 22433304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
    Yang HJ; Lee JH; Kim YJ; Yoon JH; Lee HS
    J Med Virol; 2012 Mar; 84(3):424-30. PubMed ID: 22246827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenofovir
    Rodríguez M; Pascasio JM; Fraga E; Fuentes J; Prieto M; Sánchez-Antolín G; Calleja JL; Molina E; García-Buey ML; Blanco MÁ; Salmerón J; Bonet ML; Pons JA; González JM; Casado MÁ; Jorquera F;
    World J Gastroenterol; 2017 Nov; 23(41):7459-7469. PubMed ID: 29151700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicentre trial.
    Lee SH; Cheon GJ; Kim HS; Kim SG; Kim YS; Jeong SW; Jang JY; Kim BS; Jun BG; Don Kim Y; Jun DW; Sohn JH; Kim TY; Lee BS
    Antivir Ther; 2018; 23(3):219-227. PubMed ID: 28436380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of three adefovir-based combination therapies in HBeAg-positive chronic hepatitis B patients with suboptimal response to adefovir monotherapy.
    Wang ML; Chen EQ; Zhang DM; Du LY; Yan LB; Zhou TY; Lei XZ; Lei BJ; Lu JJ; Liao J; Tang H
    J Viral Hepat; 2017 Nov; 24 Suppl 1():21-28. PubMed ID: 29082645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
    Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
    Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.